Cargando…
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report
RATIONALE: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard...
Autores principales: | Yamasaki, Masahiro, Funaishi, Kunihiko, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831270/ https://www.ncbi.nlm.nih.gov/pubmed/31415404 http://dx.doi.org/10.1097/MD.0000000000016834 |
Ejemplares similares
-
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018) -
ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report
por: Taniwaki, Masaya, et al.
Publicado: (2018) -
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018) -
Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases
por: Yamasaki, Masahiro, et al.
Publicado: (2019) -
Lymphangitis carcinomatosa from gallbladder cancer
por: Kitahara, Yoshihiro, et al.
Publicado: (2022)